Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (351-360 of 516) with videos related to

Pageof 52
Sort By:
Leukemia|November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
American Journal of Hematology|December 16, 2020
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myelomaJoselle Cook, Isla Johnson, Alexandra Higgins, et al.
Leukemia|June 17, 2024
Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 15, 2016
Myelomatous Involvement of the Central Nervous SystemJonas Paludo, Utkarsh Painuly, Shaji Kumar, et al.
Bone Marrow Transplantation|November 21, 2021
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patientsCarlyn Rose Tan, Noel Estrada-Merly, Heather Landau, et al.
JCO Oncology Practice|December 20, 2024
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing AdministrationTyler B Sandahl, Scott A Soefje, Rafael Fonseca, et al.
Leukemia|February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myelomaGayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
Pageof 52

Showing results (351-360 of 516) with videos related to

Sort By:
Pageof 52
Leukemia|November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
American Journal of Hematology|December 16, 2020
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myelomaJoselle Cook, Isla Johnson, Alexandra Higgins, et al.
Leukemia|June 17, 2024
Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 15, 2016
Myelomatous Involvement of the Central Nervous SystemJonas Paludo, Utkarsh Painuly, Shaji Kumar, et al.
Bone Marrow Transplantation|November 21, 2021
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patientsCarlyn Rose Tan, Noel Estrada-Merly, Heather Landau, et al.
JCO Oncology Practice|December 20, 2024
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing AdministrationTyler B Sandahl, Scott A Soefje, Rafael Fonseca, et al.
Leukemia|February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myelomaGayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
Pageof 52